Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Could Redwire Be the Next Rocket Lab?

Key PointsRedwire’s record Q2, with revenue up about 90% and a $542 million backlog, was driven mainly by its defense business.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at nasdaq.com →

More in Finance & Markets

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

Amgen trades at a lower valuation multiple, but Johnson & Johnson's fortress balance sheet and stronger free cash flow tell a different story about financial resilience.

  • Amgen reported $36.7B revenue in FY 2025, 10% growth, 21% net margin
  • Johnson & Johnson reported $94.2B revenue in FY 2025, 6% growth, 28.5% net margin
  • Johnson & Johnson has lower debt-to-equity ratio (0.6x) vs Amgen's 6.3x

More from Saturday 24 October →